Vitrolife AB (publ)
0YAY.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$40.51B
Close$
$204.14
31.8% downside
Current Fair Value
31.8% downsideOvervalued by 31.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $40.51 Billion |
|---|---|
| Enterprise Value | $41.32 Billion |
| Dividend Yield | $1.10 (1.15%) |
| Earnings per Share | $-28.44 |
| Beta | 1.51 |
| Outstanding Shares | 135,394,622 |
Return
| Return on Equity | -61.26% |
|---|---|
| Return on Assets | -44.08% |
| Return on Invested Capital | -44.66% |
Valuation & Multiples
| P/E Ratio | -2.6 |
|---|---|
| PEG | -8.96 |
| Price to Sales | 12.47 |
| Price to Book Ratio | 4.99 |
| Enterprise Value to Revenue | 12.23 |
| Enterprise Value to EBIT | -8.65 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.2 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 16, 2026
EPS Estimate
$0.90
Average shareholder expectationRevenue Estimate
$875.71 M
Average shareholder expectationNext Earnings Call
Expected Date
October 22, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$854.90 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Vitrolife AB
1,151 employees
CEO: Bronwyn Brophy O'Connor Vitrolife AB (publ) engages in development, production, and marketing of products for assisted reproduction. It provides oocyte retrieval needles; sperm processing; in vitro fertilization media and oil; micromanipulation pipettes; labwar...